Interestingly, APP−/− mice show a trend for increased mortality after infection [138] and a common side effect of Aβ-targeting therapies in clinical trials has been increased incidence of infections [87], although BBB disruption caused by removal of vascular amyloid could also explain this increased vulnerability [240]. The gene discussed is APP; the disease is infection.